Dana Blankenhorn

Dana Blankenhorn

InvestorPlace Contributor

Expertise: Technology, Biotech, Renewable energy

Education: M.S,J. Northwestern (Medill School) 1978; B.A. Rice University, History and Political Science 1977

Awards & Accomplishments: Tech reporter since 1982, Freelance since 1983, on Internet since 1985. Created first online coverage of Internet with a magazine, Interactive Age, 1994 Co-wrote BBS Systems for Business in 1991, Wrote Guide to Field Computing in 1992 Wrote technology history now called "Living with Moore's Law" in 2001, 2010, 2021 Author of over a dozen books, both fiction and non-fiction

About Dana:
Dana Blankenhorn has been a financial journalist since 1978, a technology journalist since 1982, and an Internet journalist since 1985. He writes a Substack newsletter, Facing the Future, which covers technology, markets, and politics.

He has written a half-dozen technology books, several novels available at the Amazon Kindle store, and covered beats ranging from education to e-commerce, and from open source to renewable energy. He lives in Atlanta.

Recent Articles

Slack Stock Heralds the Next Tech Wreck

By Dana Blankenhorn, InvestorPlace Contributor

Slack stock fell 15% after earnings, and it has a deep-pocketed partner in Amazon, but the stock is still overpriced.

Restaurant Brands International Isn’t the Only Winner of the Chicken Wars

By Dana Blankenhorn, InvestorPlace Contributor

QSR stock has kept afloat while battling over $5 chicken sandwiches as the cost of goods rises during the coronavirus pandemic.

Don’t Judge Pfizer by Its Vaccine Efforts

By Dana Blankenhorn, InvestorPlace Contributor

Pfizer hopes its cash and production infrastructure can quickly replace revenue lost in the spin-out of its generics and consumer businesses.

Bitcoin Goes Full Bart Simpson as Peaks and Valleys Dominate Weekly Chart

By Dana Blankenhorn, InvestorPlace Contributor

The price of Bitcoin is easy to manipulate, and subject to sudden swings, making it worthless as a currency, but fun to trade as an asset class.

For iBio, the Coronavirus Pandemic Was a Lucky Break

By Dana Blankenhorn, InvestorPlace Contributor

iBio's production facility could be used to manufacture a Covid-19 vaccine. It remains to be seen if IBIO stock will be a star or a bust.

Load More